"""
COMPREHENSIVE TCGA DATASET ANALYSIS FOR AI MODELING
===================================================

Executive Summary:
This report provides a detailed technical analysis of the TCGA dataset structure
and evaluates its suitability for advanced AI modeling approaches, particularly
focusing on Causal Diffusion Networks, BioCLR contrastive learning, and other
modern ML techniques.

Key Finding: The dataset contains pathway/signature scores rather than raw gene
expression data, which significantly impacts the recommended AI approaches.
"""

import pandas as pd
import numpy as np

# DATASET STRUCTURE SUMMARY
print("=" * 80)
print("TCGA DATASET COMPREHENSIVE ANALYSIS REPORT")
print("=" * 80)

dataset_summary = {
    'Total Cancer Types': 36,
    'Total Samples': 12226,
    'Feature Type': 'Pathway/Biological Signatures',
    'Feature Count': 32,
    'Sample Size Range': '45 - 1212 samples per cancer type',
    'Large Cancer Types (≥100 samples)': 29,
    'Clinical Data Status': 'Available but not accessible via pyreadr'
}

print("\n1. DATASET OVERVIEW")
print("-" * 40)
for key, value in dataset_summary.items():
    print(f"{key:.<35} {value}")

# CANCER TYPE ANALYSIS
cancer_sample_counts = {
    'BRCA': 1212, 'GBMLGG': 701, 'STES': 646, 'KIRC': 606, 'LUAD': 576,
    'THCA': 568, 'HNSC': 566, 'LUSC': 552, 'PRAD': 550, 'LGG': 530,
    'SKCM': 473, 'STAD': 450, 'COADREAD': 433, 'BLCA': 427, 'LIHC': 423,
    'COAD': 328, 'KIRP': 323, 'CESC': 309, 'OV': 307, 'SARC': 265,
    'UCEC': 201, 'ESCA': 185, 'LAML': 173, 'THYM': 119, 'PCPG': 184,
    'PAAD': 185, 'GBM': 169, 'READ': 108, 'TGCT': 156, 'UCS': 57,
    'UVM': 80, 'CHOL': 45, 'DLBC': 48, 'ACC': 79, 'MESO': 87, 'KICH': 89
}

print("\n2. SAMPLE SIZE DISTRIBUTION")
print("-" * 40)
large_cancers = {k: v for k, v in cancer_sample_counts.items() if v >= 200}
medium_cancers = {k: v for k, v in cancer_sample_counts.items() if 50 <= v < 200}
small_cancers = {k: v for k, v in cancer_sample_counts.items() if v < 50}

print(f"Large (≥200 samples): {len(large_cancers)} cancer types")
print(f"Medium (50-199 samples): {len(medium_cancers)} cancer types")
print(f"Small (<50 samples): {len(small_cancers)} cancer types")

print(f"\nTop 10 cancer types by sample size:")
top_cancers = sorted(cancer_sample_counts.items(), key=lambda x: x[1], reverse=True)[:10]
for i, (cancer, count) in enumerate(top_cancers, 1):
    print(f"  {i:2d}. {cancer}: {count:4d} samples")

# PATHWAY SIGNATURE ANALYSIS
pathway_signatures = [
    'Angio', 'ISG', 'MHCII', 'Lactate', 'PGE2', 'GM', 'LP', 'T_effect', 'T_ex',
    'lipid_associated_program3', 'proliferating', 'oxphos_program', 'Adar_gene',
    'Flcn_vivo_ko', 'Jak1_vivo_ko', 'Control_vivo_ko', 'Adar_vivo_ko',
    'Flcn_vitro_ko', 'Jak1_vitro_ko', 'Adar_vitro_ko', 'Control_vitro_ko',
    'Mac_marker', 'IFNG', 'GZMA', 'GZMB', 'PRF1', 'TBX21', 'TOX', 'PDCD1',
    'HAVCR2', 'LAG3', 'TIGIT'
]

pathway_categories = {
    'Immune Response': ['ISG', 'MHCII', 'IFNG', 'T_effect', 'T_ex', 'Mac_marker'],
    'T-cell Exhaustion': ['TOX', 'PDCD1', 'HAVCR2', 'LAG3', 'TIGIT'],
    'Cytotoxicity': ['GZMA', 'GZMB', 'PRF1', 'TBX21'],
    'Metabolism': ['Lactate', 'oxphos_program', 'lipid_associated_program3'],
    'Angiogenesis': ['Angio'],
    'Inflammation': ['PGE2'],
    'Cell Proliferation': ['proliferating'],
    'Experimental Knockouts': ['Adar_gene', 'Flcn_vivo_ko', 'Jak1_vivo_ko', 
                               'Control_vivo_ko', 'Adar_vivo_ko', 'Flcn_vitro_ko',
                               'Jak1_vitro_ko', 'Adar_vitro_ko', 'Control_vitro_ko'],
    'Other Programs': ['GM', 'LP']
}

print("\n3. PATHWAY SIGNATURE CATEGORIES")
print("-" * 40)
for category, pathways in pathway_categories.items():
    print(f"{category} ({len(pathways)}):")
    for pathway in pathways:
        print(f"  • {pathway}")
    print()

# AI MODELING FEASIBILITY
print("\n4. AI MODELING FEASIBILITY ASSESSMENT")
print("-" * 40)

approaches = {
    'BioCLR Contrastive Learning': {
        'Feasibility': 'HIGHLY SUITABLE',
        'Reasoning': [
            'Perfect dimensionality (32 features)',
            'Large sample sizes (12K+ total)',
            'Multiple cancer types for cross-domain learning',
            'Biological augmentations possible'
        ],
        'Recommended': True
    },
    'Classical ML (RF, XGBoost, SVM)': {
        'Feasibility': 'EXCELLENT',
        'Reasoning': [
            'No curse of dimensionality',
            'Interpretable features',
            'Robust performance expected',
            'Feature importance analysis'
        ],
        'Recommended': True
    },
    'Deep Learning (MLPs, Attention)': {
        'Feasibility': 'GOOD',
        'Reasoning': [
            'Shallow networks sufficient',
            'Can model pathway interactions',
            'Multi-task learning possible',
            'Attention for pathway importance'
        ],
        'Recommended': True
    },
    'Graph Neural Networks': {
        'Feasibility': 'MODERATE',
        'Reasoning': [
            'Requires external pathway networks',
            'Focus on pathway interactions',
            'Limited by predefined relationships',
            'Novel discoveries challenging'
        ],
        'Recommended': False
    },
    'Causal Discovery': {
        'Feasibility': 'MODERATE',
        'Reasoning': [
            'Small network more reliable',
            'Pathway-level causality interesting',
            'Needs clinical outcomes',
            'Limited temporal information'
        ],
        'Recommended': False
    },
    'Pseudo-temporal Reconstruction': {
        'Feasibility': 'LIMITED',
        'Reasoning': [
            'No temporal data available',
            'Cross-sectional snapshots only',
            'Would need staging information',
            'Clinical data not accessible'
        ],
        'Recommended': False
    }
}

for approach, details in approaches.items():
    status = "✓ RECOMMENDED" if details['Recommended'] else "⚠ NOT PRIORITY"
    print(f"\n{approach}")
    print(f"  Feasibility: {details['Feasibility']} {status}")
    for reason in details['Reasoning']:
        print(f"    • {reason}")

# SPECIFIC RECOMMENDATIONS
print("\n5. SPECIFIC RESEARCH RECOMMENDATIONS")
print("-" * 40)

recommendations = [
    {
        'Priority': 1,
        'Project': 'BioCLR for Pan-Cancer Pathway Learning',
        'Objective': 'Learn universal pathway representations across cancer types',
        'Approach': [
            'Simple MLP encoder (32 → 128 → 64 → 32)',
            'Pathway dropout augmentation (0.1-0.3 rate)',
            'Cross-cancer contrastive learning',
            'Transfer learning evaluation'
        ],
        'Expected_Impact': 'High - Novel methodology, strong biological basis'
    },
    {
        'Priority': 2,
        'Project': 'Pathway-Based Cancer Subtyping',
        'Objective': 'Discover pan-cancer molecular subtypes using pathway signatures',
        'Approach': [
            'Clustering in pathway space',
            'Multi-cancer subtype validation',
            'Clinical correlation analysis',
            'Survival prediction models'
        ],
        'Expected_Impact': 'High - Clinical applications, precision medicine'
    },
    {
        'Priority': 3,
        'Project': 'Pathway Interaction Networks',
        'Objective': 'Model pathway crosstalk patterns across cancer types',
        'Approach': [
            'Attention mechanisms for interactions',
            'Graph networks on pathway relationships',
            'Cancer-specific dysregulation patterns',
            'Therapeutic target identification'
        ],
        'Expected_Impact': 'Medium - Depends on pathway network quality'
    }
]

for rec in recommendations:
    print(f"\nPRIORITY {rec['Priority']}: {rec['Project']}")
    print(f"Objective: {rec['Objective']}")
    print("Technical Approach:")
    for approach in rec['Approach']:
        print(f"  • {approach}")
    print(f"Expected Impact: {rec['Expected_Impact']}")

# LIMITATIONS AND CONSIDERATIONS
print("\n6. LIMITATIONS AND CONSIDERATIONS")
print("-" * 40)

limitations = [
    "Clinical data not accessible via pyreadr (may need R or alternative tools)",
    "Pathway signatures limit fine-grained molecular analysis",
    "No temporal/longitudinal data available",
    "Limited to predefined biological processes",
    "Batch effects may exist across cancer types",
    "Normal tissue samples status unknown",
    "External validation datasets needed"
]

print("Key Limitations:")
for limitation in limitations:
    print(f"  ⚠ {limitation}")

considerations = [
    "Focus on pathway-level rather than gene-level analysis",
    "Leverage large sample sizes for robust statistical analysis",
    "Use cross-cancer validation for generalizability",
    "Consider ensemble methods for improved performance",
    "Plan for clinical validation with external datasets",
    "Document biological interpretations of findings"
]

print("\nKey Considerations:")
for consideration in considerations:
    print(f"  📋 {consideration}")

# TECHNICAL IMPLEMENTATION GUIDANCE
print("\n7. TECHNICAL IMPLEMENTATION GUIDANCE")
print("-" * 40)

implementation = {
    'Data Preprocessing': [
        'Quality control and outlier detection',
        'Normalization verification (appears pre-normalized)',
        'Batch effect assessment and correction if needed',
        'Train/validation/test splits stratified by cancer type'
    ],
    'BioCLR Implementation': [
        'Start with simple MLP architecture',
        'Implement pathway dropout augmentation',
        'Use temperature-scaled contrastive loss',
        'Evaluate embeddings with downstream tasks'
    ],
    'Validation Strategy': [
        'Cross-cancer type validation',
        'Hold-out test sets for final evaluation',
        'External dataset validation (GEO, other cohorts)',
        'Clinical correlation where possible'
    ],
    'Evaluation Metrics': [
        'Embedding quality (silhouette score, alignment)',
        'Downstream task performance (classification, clustering)',
        'Biological interpretability measures',
        'Cross-cancer transferability scores'
    ]
}

for category, items in implementation.items():
    print(f"\n{category}:")
    for item in items:
        print(f"  • {item}")

# TIMELINE AND MILESTONES
print("\n8. RECOMMENDED TIMELINE")
print("-" * 40)

timeline = [
    "Month 1-2: Data preprocessing and exploratory analysis",
    "Month 3-4: BioCLR implementation and hyperparameter tuning",
    "Month 5-6: Cross-cancer validation and transfer learning",
    "Month 7-8: Pathway interaction analysis and interpretation",
    "Month 9-10: Clinical correlation and external validation",
    "Month 11-12: Manuscript preparation and submission"
]

for milestone in timeline:
    print(f"  📅 {milestone}")

print("\n" + "=" * 80)
print("CONCLUSION")
print("=" * 80)

conclusion = """
The TCGA dataset provides an excellent foundation for pathway-based AI research.
The 32 pathway signatures across 36 cancer types (12K+ samples) offer unique
opportunities for developing novel contrastive learning approaches and
pan-cancer molecular characterization.

HIGHEST PRIORITY: BioCLR implementation for pathway signatures
- Strong technical feasibility
- Novel methodological contribution
- Clear biological interpretability
- High publication potential

The reduced dimensionality (32 vs 20K+ genes) actually provides advantages
for model development, interpretation, and generalization while maintaining
biological relevance through pathway-level analysis.
"""

print(conclusion)